Exit Orchid Pharma; pick Lupin, Sun Pharma: Avinash Gorakshakar

Avinash Gorakshakar, Market Expert told CNBC-TV18, "Orchid Pharma is a financial mess and the kind of performance in the last two-three quarters, interest costs have actually ballooned quite significantly and they still make a loss at the EBITDA level. If the investor wants to stay invested in some pharmaceutical company, then stick to some frontline pharma company like Lupin or Sun Pharmaceutical Industries and exit from Orchid because unless there is some strategic buyout, I do not think on fundamentals this stock has got any rerating trigger."At 15:12 hrs Orchid Pharma was quoting at Rs 29.20, up Rs 1.45, or 5.23 percent on the BSE.